Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class ASSE: 688266

Announcement on Voluntary Disclosure of Phase III Clinical Trial of Recombinant Human Thyrotropin β for Injection Reaching Prespecified Primary Endpoint

· Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Phase III Clinical Trial of Recombinant Human Thyrotropin β for Injection Reaching Prespecified Primary Endpoint

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Earlier from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

All Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A news releases